Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
DNA Script gets grant for longer DNA
by Melody M. Bomgardner
July 15, 2018
| A version of this story appeared in
Volume 96, Issue 29
DNA Script, a start-up based in Paris, has won $2.7 million in grants from Bpifrance, a state-backed program for French entrepreneurs. The company uses enzymes, rather than chemical processes, to assemble synthetic DNA for use in cell therapies and gene editing. It claims that its process makes longer DNA constructs more quickly and cleanly than competing approaches do. DNA Script raised $13 million in September 2017 from investors, including the venture arms of Illumina and Merck KGaA.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter